As a kind of important innate lymphocytes in vivo, Natural killer (NK) cells have a rapid and efficient capacity to recognize and destroy tumor cells, senescent cells and virus-infected cells. In the past decades, NK cells have been widely applied in the treatment of hematological malignancies in clinic, even solid tumors. Successful results have been made against hematological malignancies (NCT00697671, NCT00990717, NCT00145626), but also a number of considerable challenges have been encountered during this period, such as poor outcomes in the treatment of solid tumors, difficult to migrate to and infiltrate into tumor sites, little functioning NK cell was seen in tumor stroma. Now we know tumor microenvironment has great influence on NK cell function, phenotype and activation, and it can finally give rise to NK cell dysfunction or/and exhaustion. Many strategies have been made to try to overcome those drawbacks. In this review, we discuss the current strategies to increase the NK cell-mediated tumor cell killing capacity and homing to the solid tumor site with the aim of heightening the clinical outcome in NK cell-based immunotherapy against solid cancer.
Cite this paper
Lv, P. , Li, W. , Wang, R. , Huang, G. , Zhu, Y. and Tao, Q. (2021). Natural Killer Cell-Based Immunotherapy against Solid Cancer. Open Access Library Journal, 8, e7056. doi: http://dx.doi.org/10.4236/oalib.1107056.
Kiessling, R., Klein, E. and Wigzell, H. (1975) “Natural” Killer Cells in the Mouse. I. Cytotoxic Cells with Specificity for Mouse Moloney Leukemia Cells. Specificity and Distribution According to Genotype. European Journal of Immunology, 5, 112-117.
https://doi.org/10.1002/eji.1830050208
Campbell, K.S. and Hasegawa, J. (2013) Natural Killer Cell Biology: An Update and Future Directions. The Journal of Allergy and Clinical Immunology, 132, 536-544.
https://doi.org/10.1016/j.jaci.2013.07.006
Choucair, K., Duff, J.R., Cassidy, C.S., Albrethsen, M.T., Kelso, J.D., Lenhard, A., et al. (2019) Natural Killer Cells: A Review of Biology, Therapeutic Potential and Challenges in Treatment of Solid Tumors. Future Oncology, 15, 3053-3069.
https://doi.org/10.2217/fon-2019-0116
Dogra, P., Rancan, C., Ma, W., Toth, M., Senda, T., Carpenter, D.J., et al. (2020) Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell, 180, 749-763.e713. https://doi.org/10.1016/j.cell.2020.01.022
Hashemi, E. and Malarkannan, S. (2020) Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance. Cancers, 12, 1553.
https://doi.org/10.3390/cancers12061553
Dahlberg, C.I., Sarhan, D., Chrobok, M., Duru, A.D. and Alici, E. (2015) Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Frontiers in Immunology, 6, 605.
https://doi.org/10.3389/fimmu.2015.00605
Hueber, B., Curtis II, A.D., Kroll, K., Varner, V., Jones, R., Pathak, S., et al. (2020) Functional Perturbation of Mucosal Group 3 Innate Lymphoid and Natural Killer Cells in Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus-Infected Infant Rhesus Macaques. Journal of Virology, 94, e01644-19.
https://doi.org/10.1128/JVI.01644-19
Freud, A.G., Mundy-Bosse, B.L., Yu, J. and Caligiuri, M.A. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity, 47, 820-833.
https://doi.org/10.1016/j.immuni.2017.10.008
Stabile, H., Fionda, C., Gismondi, A. and Santoni, A. (2017) Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Frontiers in Immunology, 8, 293.
https://doi.org/10.3389/fimmu.2017.00293
Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E. and Walzer, T. (2009) Maturation of Mouse NK Cells Is a 4-Stage Developmental Program. Blood, 113, 5488-5496.
https://doi.org/10.1182/blood-2008-10-187179
Long, E.O., Kim, H.S., Liu, D., Peterson, M.E. and Rajagopalan, S. (2013) Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition. Annual Review of Immunology, 31, 227-258.
https://doi.org/10.1146/annurev-immunol-020711-075005
Abel, A.M., Yang, C., Thakar, M.S. and Malarkannan, S. (2018) Natural Killer Cells: Development, Maturation, and Clinical Utilization. Frontiers in Immunology, 9, 1869.
https://doi.org/10.3389/fimmu.2018.01869
Locatelli, F., Moretta, F., Brescia, L. and Merli, P. (2014) Natural Killer Cells in the Treatment of High-Risk Acute Leukaemia. Seminars in Immunology, 26, 173-179.
https://doi.org/10.1016/j.smim.2014.02.004
Cerwenka, A., Baron, J.L. and Lanier, L.L. (2001) Ectopic Expression of Retinoic Acid Early Inducible-1 Gene (RAE-1) Permits Natural Killer Cell-Mediated Rejection of a MHC Class I-Bearing Tumor in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 11521-11526.
https://doi.org/10.1073/pnas.201238598
Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N. and Raulet, D.H. (2000) Ligands for the Murine NKG2D Receptor: Expression by Tumor Cells and Activation of NK Cells and Macrophages. Nature Immunology, 1, 119-126.
https://doi.org/10.1038/77793
Diefenbach, A., Jensen, E.R., Jamieson, A.M. and Raulet, D.H. (2001) Rae1 and H60 Ligands of the NKG2D Receptor Stimulate Tumour Immunity. Nature, 413, 165-171.
https://doi.org/10.1038/35093109
Fauriat, C., Long, E.O., Ljunggren, H.G. and Bryceson, Y.T. (2010) Regulation of Human NK-Cell Cytokine and Chemokine Production by Target Cell Recognition. Blood, 115, 2167-2176. https://doi.org/10.1182/blood-2009-08-238469
Bryceson, Y.T., Ljunggren, H.G. and Long, E.O. (2009) Minimal Requirement for Induction of Natural Cytotoxicity and Intersection of Activation Signals by Inhibitory Receptors. Blood, 114, 2657-2666.
https://doi.org/10.1182/blood-2009-01-201632
Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., et al. (2011) Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science, 331, 44-49. https://doi.org/10.1126/science.1198687
Moretta, A., Marcenaro, E., Parolini, S., Ferlazzo, G. and Moretta, L. (2008) NK Cells at the Interface between Innate and Adaptive Immunity. Cell Death and Differentiation, 15, 226-233. https://doi.org/10.1038/sj.cdd.4402170
Zheng, M., Sun, R., Wei, H. and Tian, Z.G. (2016) NK Cells Help Induce Anti-Hepatitis B Virus CD8 T Cell Immunity in Mice. Journal of Immunology, 196, 4122-4131. https://doi.org/10.4049/jimmunol.1500846
Boyiadzis, M., Agha, M., Redner, R.L., Sehgal, A., Im, A., Hou, J.-Z., et al. (2017) Phase 1 Clinical Trial of Adoptive Immunotherapy Using “Off-the-Shelf” Activated Natural Killer Cells in Patients with Refractory and Relapsed Acute Myeloid Leukemia. Cytotherapy, 19, 1225-1232. https://doi.org/10.1016/j.jcyt.2017.07.008
Kottaridis, P.D., North, J., Tsirogianni, M., Marden, C., Samuel, E.R., Jide-Banwo, S., et al. (2015) Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. PLoS ONE, 10, e0123416.
https://doi.org/10.1371/journal.pone.0123416
Yang, Y., Lim, O., Kim, T.M., Ahn, Y.-O., Choi, H., Chung, H., et al. (2016) Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunology Research, 4, 215-224. https://doi.org/10.1158/2326-6066.CIR-15-0118
Vela, M., Corral, D., Carrasco, P., Fernández, L., Valentín, J., González, B., et al. (2018) Haploidentical IL-15/41BBL Activated and Expanded Natural Killer Cell Infusion Therapy after Salvage Chemotherapy in Children with Relapsed and Refractory Leukemia. Cancer Letters, 422, 107-117.
https://doi.org/10.1016/j.canlet.2018.02.033
Vitale, M., Cantoni, C., Pietra, G., Mingari, M.C. and Moretta, L. (2014) Effect of Tumor Cells and Tumor Microenvironment on NK-Cell Function. European Journal of Immunology, 44, 1582-1592. https://doi.org/10.1002/eji.201344272
Cremer, I., Fridman, W.H. and Sautès-Fridman, C. (2012) Tumor Microenvironment in NSCLC Suppresses NK Cells Function. OncoImmunology, 1, 244-246.
https://doi.org/10.4161/onci.1.2.18309
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., et al. (2008) Natural Killer Cells Infiltrating Human Nonsmall-Cell Lung Cancer Are Enriched in CD56BrightCD16- Cells and Display an Impaired Capability to Kill Tumor Cells. Cancer, 112, 863-875. https://doi.org/10.1002/cncr.23239
Zingoni, A., Vulpis, E., Nardone, I., Soriani, A., Fionda, C., Cippitelli, M., et al. (2016) Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy. Critical Reviews in Immunology, 36, 445-460.
https://doi.org/10.1615/CritRevImmunol.2017020166
Chitadze, G., Bhat, J., Lettau, M., Janssen, O. and Kabelitz, D. (2013) Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications. Scandinavian Journal of Immunology, 78, 120-129.
https://doi.org/10.1111/sji.12072
Ferrari de Andrade, L., Tay, R.E., Pan, D., Luoma, A.M., Ito, Y., Badrinath, S., et al. (2018) Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell-Driven Tumor Immunity. Science, 359, 1537-1542.
https://doi.org/10.1126/science.aao0505
Balsamo, M., Vermi, W., Parodi, M., Pietra, G., Manzini, C., Queirolo, P., et al. (2012) Melanoma Cells Become Resistant to NK-Cell-Mediated Killing When Exposed to NK-Cell Numbers Compatible with NK-Cell Infiltration in the Tumor. European Journal of Immunology, 42, 1833-1842.
https://doi.org/10.1002/eji.201142179
Nayyar, G., Chu, Y. and Cairo, M.S. (2019) Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Frontiers in Oncology, 9, 51.
https://doi.org/10.3389/fonc.2019.00051
Stojanovic, A. and Cerwenka, A. (2011) Natural Killer Cells and Solid Tumors. Journal of Innate Immunity, 3, 355-364. https://doi.org/10.1159/000325465
Carlsten. M., Norell. H., Bryceson. Y.T., Poschke, I., Schedvins, K., Ljunggren, H.-G., et al. (2009) Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells. Journal of Immunology, 183, 4921-4930. https://doi.org/10.4049/jimmunol.0901226
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., et al. (2003) Transforming Growth Factor Beta 1 Inhibits Expression of NKp30 and NKG2D Receptors: Consequences for the NK-Mediated Killing of Dendritic Cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 4120-4125. https://doi.org/10.1073/pnas.0730640100
Marcenaro, E., Della Chiesa, M., Bellora, F., Parolini, S., Millo, R., Moretta, L., et al. (2005) IL-12 or IL-4 Prime Human NK Cells to Mediate Functionally Divergent Interactions with Dendritic Cells or Tumors. Journal of Immunology, 174, 3992-3998.
https://doi.org/10.4049/jimmunol.174.7.3992
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., et al. (2012) Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. Cancer Research, 72, 1407-1415.
https://doi.org/10.1158/0008-5472.CAN-11-2544
Batlle, E. and Massagué, J. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity, 50, 924-940.
https://doi.org/10.1016/j.immuni.2019.03.024
Feng, Y., Xiong, Y., Qiao, T., Li, X., Jia, L., Han, Y., et al. (2018) Lactate Dehydrogenase A: A Key Player in Carcinogenesis and Potential Target in Cancer Therapy. Cancer Medicine, 7, 6124-6136. https://doi.org/10.1002/cam4.1820
Augsten, M. (2014) Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment. Frontiers in Oncology, 4, 62.
https://doi.org/10.3389/fonc.2014.00062
Lee, J.C., Lee, K.M., Kim, D.W. and Heo, D.S. (2004) Elevated TGF-Betal Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. Journal of Immunology, 172, 7335-7340.
https://doi.org/10.4049/jimmunol.172.12.7335
Viel, S., Marçais, A., Guimaraes, F.S., Loftus, R., Rabilloud, J., Grau, M., et al. (2016) TGF-β Inhibits the Activation and Functions of NK Cells by Repressing the mTOR Pathway. Science Signaling, 9, ra19. https://doi.org/10.1126/scisignal.aad1884
Slattery, K., Zaiatz-Bittencourt, V., Woods, E., Brennan, K., Marks, S., Chew, S., et al. (2019) TGFβ Drives Mitochondrial Dysfunction in Peripheral Blood NK Cells during Metastatic Breast Cancer. bioRxiv, Article ID: 648501.
https://doi.org/10.1101/648501
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S.S., Young, A., Ngiow, S.F., et al. (2017) Tumor Immunoevasion by the Conversion of Effector NK Cells Into Type 1 Innate Lymphoid Cells. Nature Immunology, 18, 1004-1015.
https://doi.org/10.1038/ni.3800
Mehta, R.S., Randolph, B., Daher, M. and Rezvani, K. (2018) NK Cell Therapy for Hematologic Malignancies. International Journal of Hematology, 107, 262-270.
https://doi.org/10.1007/s12185-018-2407-5
Mehta, R.S. and Rezvani, K. (2016) Immune Reconstitution Post Allogeneic Transplant and the Impact of Immune Recovery on the Risk of Infection. Virulence, 7, 901-916.
https://doi.org/10.1080/21505594.2016.1208866
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., et al. (2015) Phase I Clinical Trial of Autologous NK Cell Therapy Using Novel Expansion Method in Patients with Advanced Digestive Cancer. Journal of Translational Medicine, 13, Article No. 277. https://doi.org/10.1186/s12967-015-0632-8
Parkhurst, M.R., Riley, J.P., Dudley, M.E. and Rosenberg, S.A. (2011) Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression. Clinical Cancer Research, 17, 6287-6297. https://doi.org/10.1158/1078-0432.CCR-11-1347
Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., et al. (2011) A Phase II Study of Allogeneic Natural Killer Cell Therapy to Treat Patients with Recurrent Ovarian and Breast Cancer. Cytotherapy, 13, 98-107.
https://doi.org/10.3109/14653249.2010.515582
Pérez-Martínez, A., Fernández, L., Valentín, J., Martínez-Romera, I., Corral, M.D., Ramírez, M., et al. (2015) A Phase I/II Trial of Interleukin-15—Stimulated Natural Killer Cell Infusion after Haplo-Identical Stem Cell Transplantation for Pediatric Refractory Solid Tumors. Cytotherapy, 17, 1594-1603.
https://doi.org/10.1016/j.jcyt.2015.07.011
Iliopoulou, E.G., Kountourakis, P., Karamouzis, M.V., Doufexis, D., Ardavanis, A., Baxevanis, C.N., et al. (2010) A Phase I Trial of Adoptive Transfer of Allogeneic Natural Killer Cells in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 59, 1781-1789.
https://doi.org/10.1007/s00262-010-0904-3
Tonn, T., Schwabe, D., Klingemann, H.G., Becker, S., Esser, R., Koehl, U., et al. (2013) Treatment of Patients with Advanced Cancer with the Natural Killer Cell Line NK-92. Cytotherapy, 15, 1563-1570. https://doi.org/10.1016/j.jcyt.2013.06.017
Zhu, H., Blum, R.H., Bernareggi, D., Heggernes Ask, E., Wu, Z., Hoel, H.J., et al. (2020) Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes in Vivo Persistence and Enhances Anti-Tumor Activity. Cell Stem Cell, 27, 224-237.e226. https://doi.org/10.1016/j.stem.2020.05.008
Woll, P.S., Grzywacz, B., Tian, X., Marcus, R.K., Knorr, D.A., Verneris, M.R., et al. (2009) Human Embryonic Stem Cells Differentiate into a Homogeneous Population of Natural Killer Cells with Potent in Vivo Antitumor Activity. Blood, 113, 6094-6101.
https://doi.org/10.1182/blood-2008-06-165225
Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., et al. (2015) Engineering NK Cells Modified with an EGFRvIII-Specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-Secreting Glioblastoma. Journal of Immunotherapy, 38, 197-210.
https://doi.org/10.1097/CJI.0000000000000082
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., et al. (2008) Engineering Antigen-Specific Primary Human NK Cells against HER-2 Positive Carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 105, 17481-17486.
https://doi.org/10.1073/pnas.0804788105
Posey Jr., A.D., Schwab, R.D., Boesteanu, A.C., Steentoft, C., Mandel, U., Engels, B., et al. (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity, 44, 1444-1454.
https://doi.org/10.1016/j.immuni.2016.05.014
Souza-Fonseca-Guimaraes, F., Cursons, J. and Huntington, N.D. (2019) The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends in Immunology, 40, 142-158. https://doi.org/10.1016/j.it.2018.12.003
Park, J., Wrzesinski, S.H., Stern, E., Look, M., Criscione, J., Ragheb, R., et al. (2012) Combination delivery of TGF-β Inhibitor and IL-2 by Nanoscale Liposomal Polymeric Gels Enhances Tumour Immunotherapy. Nature Materials, 11, 895-905.
https://doi.org/10.1038/nmat3355
Otegbeye, F., Ojo, E., Moreton, S., Mackowski, N., Lee, D.A., de Lima, M., et al. (2018) Inhibiting TGF-Beta Signaling Preserves the Function of Highly Activated, in Vitro Expanded Natural Killer Cells in AML and Colon Cancer Models. PLoS ONE, 13, e0191358. https://doi.org/10.1371/journal.pone.0191358
Tchou, J., Zhao, Y., Levine, B.L., Zhang, P.J., Davis, M.M., Joseph Melenhorst, J., et al. (2017) Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunology Research, 5, 1152-1161. https://doi.org/10.1158/2326-6066.CIR-17-0189
Priceman, S.J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J.P., Park, A.K., et al. (2018) Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 24, 95-105. https://doi.org/10.1158/1078-0432.CCR-17-2041
Nellan, A., Rota, C., Majzner, R., Lester-McCully, C.M., Griesinger, A.M., Mulcahy Levy, J.M., et al. (2018) Durable Regression of Medulloblastoma after Regional and Intravenous Delivery of Anti-HER2 Chimeric Antigen Receptor T Cells. Journal for Immunotherapy of Cancer, 6, 30. http://dx.doi.org/10.1186/s40425-018-0340-z
Katz, S.C., Point, G.R., Cunetta, M., Thorn, M., Guha, P., Espat, N.J., et al. (2016) Regional CAR-T Cell Infusions for Peritoneal Carcinomatosis Are Superior to Systemic Delivery. Cancer Gene Therapy, 23, 142-148.
https://doi.org/10.1038/cgt.2016.14
Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S. (2008) Functions of Natural Killer Cells. Nature Immunology, 9, 503-510.
https://doi.org/10.1038/ni1582
Adotevi, O., Godet, Y., Galaine, J., Lakkis, Z., Idirene, I., Certoux, J.M., et al. (2018) In Situ Delivery of Allogeneic Natural Killer Cell (NK) Combined with Cetuximab in Liver Metastases of Gastrointestinal Carcinoma: A Phase I Clinical Trial. OncoImmunology, 7, Article ID: e1424673.
https://doi.org/10.1080/2162402X.2018.1424673
Mortier, E., Woo, T., Advincula, R., Gozalo, S. and Ma, A. (2008) IL-15Ralpha Chaperones IL-15 to Stable Dendritic Cell Membrane Complexes That Activate NK Cells via Trans Presentation. The Journal of Experimental Medicine, 205, 1213-1225.
https://doi.org/10.1084/jem.20071913
Hennessy, R.J., Pham, K., Delconte, R., Rautela, J., Hodgkin, P.D. and Huntington, N.D. (2019) Quantifying NK Cell Growth and Survival Changes in Response to Cytokines and Regulatory Checkpoint Blockade Helps Identify Optimal Culture and Expansion Conditions. Journal of Leukocyte Biology, 105, 1341-1354.
https://doi.org/10.1002/JLB.MA0718-296R
Strengell, M., Matikainen, S., Sirén, J., Lehtonen, A., Foster, D., Julkunen, I., et al. (2003) IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-Gamma Production in Human NK and T Cells. Journal of Immunology, 170, 5464-5469.
https://doi.org/10.4049/jimmunol.170.11.5464
Lusty, E., Poznanski, S.M., Kwofie, K., Mandur, T.S., Lee, D.A., Richards, C.D., et al. (2017) IL-18/IL-15/IL-12 Synergy Induces Elevated and Prolonged IFN-γ Production by ex Vivo Expanded NK Cells Which Is Not Due to Enhanced STAT4 Activation. Molecular Immunology, 88, 138-147.
https://doi.org/10.1016/j.molimm.2017.06.025
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J.G., Yu, Z.Y., et al. (2013) Inhibiting Glycolytic Metabolism Enhances CD8 T Cell Memory and Antitumor Function. The Journal of Clinical Investigation, 123, 4479-4488.
https://doi.org/10.1172/JCI69589
Crompton, J.G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R.L., et al. (2015) Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 75, 296-305.
https://doi.org/10.1158/0008-5472.CAN-14-2277
Naeimi Kararoudi, M., Dolatshad, H., Trikha, P., Hussain, S.-R.A., Elmas, E., Foltz, J.A., et al. (2018) Generation of Knock-Out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. Journal of Visualized Experiments, No. 136, 58237. https://doi.org/10.3791/58237
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S.D., et al. (2012) NK Cells Engineered to Express a GD2 -Specific Antigen Receptor Display Built-in ADCC-Like Activity against Tumour Cells of Neuroectodermal Origin. Journal of Cellular and Molecular Medicine, 16, 569-581.
https://doi.org/10.1111/j.1582-4934.2011.01343.x
Sahm, C., Schönfeld, K. and Wels, W.S. (2012) Expression of IL-15 in NK Cells Results in Rapid Enrichment and Selective Cytotoxicity of Gene-Modified Effectors That Carry a Tumor-Specific Antigen Receptor. Cancer Immunology, Immunotherapy, 61, 1451-1461. https://doi.org/10.1007/s00262-012-1212-x
Zhang, C., Burger, M.C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., et al. (2016) ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 108, djv375.
https://doi.org/10.1093/jnci/djv375
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., et al. (2008) Infusion of the Allogeneic Cell Line NK-92 in Patients with Advanced Renal Cell Cancer or Melanoma: A Phase I Trial. Cytotherapy, 10, 625-632.
https://doi.org/10.1080/14653240802301872
Yuan, X., Wu, H., Bu, H., Zhou, J. and Zhang, H. (2019) Targeting the Immunity Protein Kinases for Immuno-Oncology. European Journal of Medicinal Chemistry, 163, 413-427. https://doi.org/10.1016/j.ejmech.2018.11.072
Spolski, R., Li, P. and Leonard, W.J. (2018) Biology and Regulation of IL-2: From Molecular Mechanisms to human Therapy. Nature Reviews Immunology, 18, 648-659.
https://doi.org/10.1038/s41577-018-0046-y